The 37-amino acid vasodilator behind eight FDA-approved migraine drugs — and why CGRP's story rewrites what peptide therapeutics can achieve

Calcitonin gene-related peptide is one of the most potent vasodilators your body produces. Released by sensory nerves wrapped around blood vessels in the brain, CGRP triggers the cascade of events — vessel dilation, inflammation, pain signaling — that defines a migraine attack. The 1993 discovery that CGRP levels spike in jugular blood during migraines launched a 25-year translational sprint that culminated in an entire drug class.

The anti-CGRP therapeutic landscape now includes four monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and four small-molecule receptor antagonists called gepants (ubrogepant, rimegepant, atogepant, zavegepant). Together, they represent the most successful peptide-targeted drug development program in modern pharmacology — and they transformed migraine from a condition managed primarily with repurposed medications into one with purpose-built, mechanism-specific treatments.

This article examines the peptide biology of CGRP itself, the evidence behind each class of anti-CGRP therapy, the unresolved question of long-term cardiovascular safety, and what this development story means for the broader peptide therapeutics landscape. Whether you are a clinician evaluating anti-CGRP options, a researcher studying peptide signaling, or a patient trying to understand why your neurologist recommended one of these drugs — the evidence is here, cited, and contextualized.

Quick Facts: CGRP at a Glance

What Is CGRP?

Pronunciation: C-G-R-P

Your brain is trying to protect you, and sometimes that protection feels like it is trying to kill you. During a migraine, a 37-amino acid peptide called CGRP floods the space around blood vessels in your skull, triggering vasodilation, inflammation, and a cascade of pain signals that can disable you for hours or days. The same molecule that helps regulate blood flow and protect your heart under normal conditions becomes, in the wrong context, the molecular engine of one of the most common neurological disorders on the planet.

Calcitonin gene-related peptide exists in two isoforms — α-CGRP, encoded by the CALCA gene through alternative splicing of the calcitonin gene, and β-CGRP, encoded by the separate CALCB gene and differing by just three amino acids in humans. Alpha-CGRP dominates in the trigeminal ganglia and sensory nervous system; beta-CGRP is more prevalent in the enteric nervous system. Both are among the most potent endogenous vasodilators known — 10 to 1,000 times more potent than classic vasodilators like acetylcholine or substance P.

The CGRP story is unusual for Peptidings because the compound itself is not what people take. No one injects CGRP. Instead, eight FDA-approved drugs exist specifically to block CGRP or its receptor — monoclonal antibodies and small-molecule antagonists that represent the most successful peptide-targeted drug development program in history. This article covers the peptide biology, the drugs that target it, and why this story matters for understanding what rigorous peptide science can achieve.

Origins and Discovery

The CGRP story begins with an accident of molecular biology. In 1982, Susan Amara and colleagues at the University of California, San Diego, were studying how the calcitonin gene produced its protein product when they discovered something unexpected: the same gene, through alternative RNA splicing, could produce an entirely different peptide in neural tissue. They named it calcitonin gene-related peptide — a 37-amino acid molecule that shared only modest homology with calcitonin but was expressed abundantly in sensory neurons throughout the nervous system.

The migraine connection came eleven years later. In 1993, Peter Goadsby and Lars Edvinsson collected blood from the jugular vein of patients during migraine attacks and found that CGRP levels were markedly elevated compared to headache-free periods (PMID 6283379). This was a landmark observation — it placed a specific, measurable peptide at the scene of the crime during active migraine attacks. When Lassen and colleagues showed in 2002 that intravenous CGRP infusion could trigger migraine-like headache in migraineurs (PMID 11993614), the target was validated: block CGRP, prevent migraines.

The translational sprint from Goadsby's 1993 observation to the first FDA approval (erenumab, May 2018) took 25 years — fast by drug development standards, and remarkably efficient for a pathway that required building an entirely new drug class. The early gepants (olcegepant, telcagepant) failed due to hepatotoxicity, but the class survived. By 2023, eight anti-CGRP therapeutics had reached the market. No other peptide pathway has produced anything comparable.

Mechanism of Action

CGRP Signaling: The Endogenous Pathway

CGRP acts through a receptor complex that is unusual in peptide pharmacology. The calcitonin-like receptor (CLR) requires a chaperone protein — receptor activity-modifying protein 1 (RAMP1) — to form a functional receptor. Without RAMP1, CLR cannot reach the cell surface or bind CGRP with high affinity. This heterodimeric requirement (CLR + RAMP1) provides tissue specificity: only cells expressing both proteins respond to CGRP.

When CGRP binds the CLR/RAMP1 complex, it activates the Gαs signaling cascade: adenylyl cyclase → cyclic AMP → protein kinase A. In vascular smooth muscle, this produces potent vasodilation. In trigeminal neurons, it drives neurogenic inflammation — mast cell degranulation, plasma protein extravasation, and the release of additional inflammatory mediators. In the trigeminal nucleus caudalis (the brainstem relay for head pain), CGRP contributes to central sensitization, the process that turns a headache into a throbbing, light-sensitive, nausea-inducing migraine.

Anti-CGRP Monoclonal Antibodies

Four monoclonal antibodies target the CGRP pathway, but they do not all hit the same target. Erenumab (Aimovig) is the only one that blocks the receptor — it binds the CLR/RAMP1 complex directly. Fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti) all target the CGRP ligand itself, binding and neutralizing the peptide before it can reach any receptor. Both strategies work. The clinical outcomes are broadly similar, though head-to-head comparisons are limited.

The monoclonal antibody approach offers several pharmacological advantages: long half-lives (26–31 days) allow monthly or quarterly dosing, high target specificity minimizes off-target effects, and the large molecular size means minimal central nervous system penetration — the drugs work primarily at peripheral sites, outside the blood-brain barrier.

Gepants: Small-Molecule Receptor Antagonists

The gepants (ubrogepant, rimegepant, atogepant, zavegepant) are small molecules that competitively block the CGRP receptor. Unlike the antibodies, gepants have short half-lives (6–11 hours) and can be taken orally or intranasally. This makes them suitable for both acute treatment (take when a migraine starts) and prevention (take daily to reduce migraine frequency).

The gepant class had a rocky start. The first-generation gepants — olcegepant (IV only, never marketed) and telcagepant — were abandoned due to hepatotoxicity signals. Current gepants have acceptable hepatic safety profiles, but the liver injury history means long-term hepatic monitoring remains part of the clinical conversation.

Rimegepant is unique among the gepants: it carries a dual indication for both acute treatment and preventive use, the only anti-CGRP agent approved for both contexts.

Beyond Migraine: CGRP's Cardiovascular Role

CGRP is not just a migraine molecule. In the cardiovascular system, it is a potent vasodilator and cardioprotective agent. During ischemic events, CGRP release from sensory nerves in the heart helps maintain coronary blood flow and reduce infarct size. Animal studies in CGRP-knockout mice show increased susceptibility to cardiac injury under stress conditions.

This raises a legitimate but unresolved concern: what happens when you chronically block CGRP in patients who also have cardiovascular disease? The pivotal anti-CGRP trials largely excluded patients with significant cardiovascular comorbidities. Seven-plus years of post-marketing data have not revealed a cardiovascular safety signal, but the theoretical risk remains a topic of active investigation — particularly as anti-CGRP use expands to older populations with higher baseline cardiovascular risk.

Key Research Areas and Studies

The Monoclonal Antibody Pivotal Trials

The evidence base for anti-CGRP monoclonal antibodies rests on a series of large, well-designed Phase 3 randomized controlled trials — each enrolling hundreds to over a thousand patients.

Erenumab — STRIVE (PMID 29171821): This Phase 3 RCT enrolled 955 patients with episodic migraine and randomized them to erenumab 70 mg, 140 mg, or placebo monthly for 6 months. The 70 mg dose reduced monthly migraine days by 3.2 versus 1.8 for placebo. The 140 mg dose achieved a 3.7-day reduction. The 50% responder rate (the proportion of patients whose migraines dropped by at least half) was 43.3% for the 70 mg dose and 50.0% for the 140 mg dose, versus 26.6% for placebo. These numbers define the clinical reality: anti-CGRP mAbs do not eliminate migraines for most patients, but they meaningfully reduce the burden.

Fremanezumab — HALO (PMID 29537315): Enrolled 1,130 patients with chronic migraine. Both quarterly (675 mg loading, then 225 mg × 2) and monthly (225 mg) dosing schedules reduced monthly headache days by approximately 4.5 versus 2.5 for placebo. Quarterly dosing is a key differentiator — one injection every three months.

Galcanezumab — EVOLVE-1 (PMID 30415693): 858 patients with episodic migraine. The 120 mg dose reduced monthly migraine days by 4.7 versus 2.8 for placebo. The 50% responder rate reached 62.3% — one of the highest in the class. Galcanezumab also carries the only FDA approval for episodic cluster headache (2019), based on the ACT-1 trial.

Eptinezumab — PROMISE-2 (PMID 32146626): 1,072 patients with chronic migraine. The 100 mg IV quarterly dose reduced monthly migraine days by 3.9 versus 3.2 for placebo. Eptinezumab is the only IV-administered anti-CGRP mAb, infused every 3 months — advantageous for patients who want physician-administered dosing.

The Gepant Evidence

Ubrogepant — ACHIEVE I/II (PMID 33658706): Combined analysis of two Phase 3 RCTs in acute migraine. Pain freedom at 2 hours: 19.2–21.2% for ubrogepant 50/100 mg versus 11.8% for placebo. Absence of most bothersome symptom at 2 hours: 37.7–38.9% versus 27.4%.

Rimegepant — Dual-Indication (PMID 36104572): Phase 3 data supporting both acute treatment (75 mg as needed) and preventive use (75 mg every other day). The only anti-CGRP agent with both indications.

Atogepant — ADVANCE (PMID 38176842): 910 patients with episodic migraine. Daily oral atogepant 30 mg or 60 mg significantly reduced monthly migraine days versus placebo. The first gepant specifically developed for prevention.

Long-Term Safety Data

Erenumab has the longest follow-up among anti-CGRP agents: open-label extension data through 5 years (PMID 30670654) in 383 patients show sustained efficacy without new safety signals. The most common adverse events remain injection site reactions and constipation. The constipation signal is interesting mechanistically — CGRP promotes gastrointestinal motility, so receptor blockade (erenumab is the receptor-targeting mAb) logically slows gut transit.

No serious cardiovascular adverse events have emerged in clinical trials or post-marketing surveillance. However, the pivotal trials excluded patients with significant cardiovascular history, and the median age of trial participants was 40–45 years. The cardiovascular safety question remains relevant for the expanding real-world population.

Claims vs. Evidence

The Human Evidence Landscape

The human evidence for CGRP-targeted therapeutics is among the most extensive in all of peptide pharmacology. Over 7,600 patients were enrolled across the pivotal Phase 3 monoclonal antibody trials alone (STRIVE: 955, HALO: 1,130, EVOLVE-1: 858, PROMISE-2: 1,072, plus additional Phase 2 and extension studies). The gepant program adds several thousand more. When including Phase 2 dose-finding studies, open-label extensions, and real-world observational cohorts, the total human exposure base exceeds 50,000 patient-years.

Study Quality Assessment

The pivotal trials are uniformly high quality: randomized, double-blind, placebo-controlled, multicenter, with pre-specified primary endpoints and adequate power. The primary endpoint (change in monthly migraine days) is clinically meaningful and directly patient-relevant — not a surrogate biomarker. The secondary endpoints (50% responder rate, medication-free days, functional disability scores) reinforce the primary results.

What the Human Data Show — and What They Do Not

The data unambiguously demonstrate that anti-CGRP therapeutics reduce migraine frequency and burden. The effect sizes are moderate (3–5 fewer migraine days per month) but clinically meaningful for a condition with few well-tolerated preventive options. Long-term data through 5 years confirm sustained efficacy.

What the data do not show is cardiovascular safety in high-risk populations. The pivotal trials enrolled predominantly young-to-middle-aged patients (median age 40–45) without significant cardiovascular history. The extension studies maintained similar demographics. Post-marketing pharmacovigilance has not identified a signal, but absence of evidence in a selected population is not evidence of absence in a broader one.

Comparison to the Broader Cardiovascular Evidence

Compared to the other cardiovascular compounds — eptifibatide (>36,000 in RCTs), bivalirudin (>36,000), and even nesiritide (7,141 in ASCEND-HF) — the CGRP therapeutic evidence base is comparable in scale and superior in consistency. The anti-CGRP story is one of convergent evidence: multiple drugs, multiple mechanisms (ligand vs. receptor targeting, mAbs vs. small molecules), all producing concordant results.

Safety, Risks, and Limitations

Anti-CGRP Monoclonal Antibodies

Injection site reactions are the most frequently reported adverse event across all four subcutaneous mAbs. These include pain, redness, and swelling at the injection site — typically mild and transient.

Constipation is a class-effect concern primarily associated with erenumab (the receptor-targeting mAb). CGRP promotes gastrointestinal motility; blocking its receptor in the gut logically slows transit. The ligand-targeting mAbs (fremanezumab, galcanezumab) show lower constipation rates, though the mechanism is not fully explained — free CGRP that reaches gut receptors may still signal when the ligand-targeting mAbs are present.

Antibody development occurs at low rates (less than 6% for most agents) and has not been consistently associated with reduced efficacy or safety concerns.

Hypertension has been reported in post-marketing surveillance for erenumab specifically. FDA updated the label in 2021 to include hypertension as a warning. The mechanism may relate to CGRP's vasodilatory role — blocking the receptor could theoretically increase vascular tone.

Gepant Safety

Nausea is the most common adverse event across the gepant class. Rates in Phase 3 trials ranged from 2–5%, modestly above placebo.

Hepatotoxicity is the historical concern. First-generation gepants telcagepant and MK-3207 were discontinued for liver injury signals. Current gepants (ubrogepant, rimegepant, atogepant, zavegepant) have shown acceptable hepatic safety in Phase 3 trials and open-label extensions. However, the class history means that liver function should be considered in clinical decision-making, particularly for patients taking hepatotoxic co-medications.

The Cardiovascular Safety Question

This is the outstanding question in CGRP therapeutics — not because evidence of harm exists, but because the theoretical rationale for concern is biologically sound and the population at theoretical risk was underrepresented in clinical trials.

CGRP is a potent vasodilator and has demonstrated cardioprotective effects in animal models of ischemia. CGRP-knockout mice show increased susceptibility to cardiac injury. Chronic blockade of this pathway could theoretically impair compensatory vasodilation during ischemic events.

The evidence to date is reassuring: no cardiovascular signal in Phase 3 trials, open-label extensions through 5 years, or post-marketing pharmacovigilance databases. The AAN/AHS and ACC/AHA have not restricted anti-CGRP use based on cardiovascular concerns. However, clinicians treating patients with unstable angina, recent myocardial infarction, or peripheral vascular disease should weigh this theoretical risk against the established migraine benefit.

Legal and Regulatory Status

All eight anti-CGRP therapeutics are FDA-approved prescription medications. None are controlled substances. None are available through compounding pharmacies or gray-market research chemical vendors — this is a fully regulated pharmaceutical drug class.

Monoclonal antibodies: - Erenumab (Aimovig) — FDA approved May 2018. First anti-CGRP agent. SC monthly injection. - Fremanezumab (Ajovy) — FDA approved September 2018. SC monthly or quarterly. - Galcanezumab (Emgality) — FDA approved September 2018. SC monthly. Also approved for episodic cluster headache (June 2019). - Eptinezumab (Vyepti) — FDA approved February 2020. IV quarterly infusion. The only IV-administered anti-CGRP agent.

Gepants: - Ubrogepant (Ubrelvy) — FDA approved December 2019. Oral, acute treatment. - Rimegepant (Nurtec ODT) — FDA approved February 2020 (acute); expanded to preventive indication May 2021. Oral disintegrating tablet, dual acute/preventive. - Atogepant (Qulipta) — FDA approved September 2021. Oral, preventive. - Zavegepant (Zavzpret) — FDA approved March 2023. Intranasal, acute treatment.

AAN/AHS guideline status: Class I recommendation (highest level) for anti-CGRP mAbs in migraine prevention. Gepants recommended at varying levels for acute and/or preventive treatment depending on agent and indication.

WADA: Not prohibited. Anti-CGRP agents are not performance-enhancing.

International: EMA approvals for erenumab, fremanezumab, galcanezumab (EU). Gepant approvals vary by region. Eptinezumab EMA approved under Vyepti.

Research Protocols and Formulation Considerations

Monoclonal Antibodies

Anti-CGRP mAbs are supplied as pre-filled syringes or auto-injectors (SC agents) or single-use vials (eptinezumab, IV). No reconstitution is required for the SC formulations — they are ready-to-use. Storage at 2–8°C (36–46°F); may be stored at room temperature (up to 25°C / 77°F) for limited periods per package labeling.

Administration timing: SC mAbs are self-administered at home. Eptinezumab requires IV infusion in a healthcare setting (approximately 30 minutes per infusion, every 3 months).

Gepants

All oral gepants are supplied as tablets or orally disintegrating tablets. No special storage requirements beyond controlled room temperature. Zavegepant is supplied as a nasal spray device.

Dosing flexibility: Rimegepant's dual indication means it can be used as needed for acute attacks AND as every-other-day prevention — a unique pharmacological profile in the class.

Research Considerations for Investigators

CGRP remains an active research target. Ongoing investigations include: - Anti-CGRP use in post-traumatic headache (several Phase 3 trials ongoing) - Medication-overuse headache (rimegepant data emerging) - Fibromyalgia and chronic pain syndromes (CGRP's role in central sensitization) - Cardiovascular outcomes studies in higher-risk populations - Biomarkers predicting anti-CGRP response (CGRP levels, calcitonin levels)

Dosing in Published Research

The following table summarizes dosing protocols for CGRP as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.

Approved Monoclonal Antibody Dosing

Approved Gepant Dosing

Dosing in Self-Experimentation Communities

There is no meaningful self-experimentation community for CGRP-targeted therapeutics. All eight approved agents are prescription pharmaceuticals manufactured by major pharmaceutical companies (Amgen, Teva, Eli Lilly, Lundbeck, AbbVie, Pfizer, Biohaven). They are not available through compounding pharmacies, research chemical vendors, or gray-market peptide suppliers.

Endogenous CGRP itself is a 37-amino acid peptide with a 6.9-minute half-life that serves no self-administration purpose. No community protocols exist for CGRP administration.

This section is included for structural consistency across Peptidings compound articles. The absence of a self-experimentation ecosystem is itself informative — it reflects what fully developed pharmaceutical markets look like for peptide targets that have completed the translational pipeline.

Combination Stacks

Research into CGRP combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining CGRP with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

CGRP is the most successful peptide-to-therapeutic translation story in modern medicine. From Peter Goadsby's 1993 observation of elevated CGRP in jugular blood during migraine attacks to eight FDA-approved drugs targeting one peptide pathway, the CGRP story defines what rigorous, sustained, evidence-driven peptide drug development looks like.

The anti-CGRP therapeutic class includes four monoclonal antibodies — erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti) — and four small-molecule gepants: ubrogepant (Ubrelvy), rimegepant (Nurtec ODT), atogepant (Qulipta), and zavegepant (Zavzpret). Together, they transformed migraine treatment from reliance on repurposed medications to purpose-built, mechanism-specific therapeutics.

The evidence base is enormous: over 7,600 patients in pivotal mAb trials alone, with consistent 3–5 day reductions in monthly migraine days and 50% responder rates ranging from 40% to 62%. Long-term data through 5 years confirm sustained efficacy without tolerance. The outstanding question — cardiovascular safety of chronic CGRP blockade — remains theoretical after 7+ years of post-marketing surveillance.

For Peptidings readers encountering earlier-stage peptides elsewhere on this site, CGRP provides the reference point. This is what the full translational pipeline looks like when the science, the clinical development, and the regulatory pathway all work. Most peptides never get here. CGRP did.

Verdict Recapitulation

Eight FDA-approved therapeutics. Class I guideline recommendation. Thousands of patients in high-quality RCTs. Five-year safety data. Clear mechanism. Convergent evidence across multiple drug classes. This is as solid as peptide therapeutics get — and the benchmark against which every other compound on Peptidings should be measured.

For readers considering CGRP, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Compound	Type	Evidence Tier	Verdict	Mechanism	Primary Use Case	Human Data	FDA Status	WADA Status	Key Limitation
CGRP (Anti-CGRP Therapeutics)	37-AA endogenous neuropeptide; 8 approved antagonists (mAbs + gepants)	Tier 1 — Approved Drug	Strong Foundation	CLR/RAMP1 receptor blockade (mAbs target ligand or receptor; gepants target receptor); reduces trigeminovascular activation and neurogenic inflammation	Migraine prevention and acute treatment; cluster headache	>7,600 in cited trials; 8 FDA-approved drugs	FDA-approved (erenumab 2018, fremanezumab 2018, galcanezumab 2018, eptinezumab 2020, ubrogepant 2019, rimegepant 2020, atogepant 2021, zavegepant 2023)	Not prohibited	Cardiovascular safety of chronic CGRP blockade still under surveillance; most CV-risk patients excluded from pivotal trials
Nesiritide	32-AA recombinant human BNP (rhBNP)	Tier 1 — Approved Drug	Eyes Open	NPR-A → cGMP → vasodilation + natriuresis + RAAS suppression; identical to endogenous BNP	Acute decompensated heart failure (hemodynamic relief)	>24,000 in cited trials; 7,141 in ASCEND-HF alone	FDA-approved 2001; Class IIb (downgraded)	Not prohibited	No mortality or rehospitalization benefit (ASCEND-HF); largely superseded by sacubitril/valsartan; IV-only
Eptifibatide	Cyclic heptapeptide GP IIb/IIIa inhibitor (snake venom–derived)	Tier 1 — Approved Drug	Strong Foundation	Competitive reversible GP IIb/IIIa (αIIbβ3) integrin blockade via KGD pharmacophore → prevents fibrinogen-mediated platelet cross-linking	Acute coronary syndromes; PCI antiplatelet adjunct	>45,000 in cited trials; 10,948 in PURSUIT alone	FDA-approved 1998; Class IIa	Not prohibited	Higher bleeding risk than newer alternatives; IV-only; declining use due to potent oral P2Y12 inhibitors
Bivalirudin	20-AA bivalent direct thrombin inhibitor (leech hirudin–inspired)	Tier 1 — Approved Drug	Strong Foundation	Bivalent thrombin inhibition (active site + exosite 1); self-cleavage at Arg3-Pro4 → self-regulating anticoagulation; inhibits clot-bound thrombin	PCI anticoagulant; HIT patients; STEMI intervention	>41,000 in cited trials; 13,819 in ACUITY alone	FDA-approved 2000; Class IIa	Not prohibited	Slightly higher acute stent thrombosis (short half-life); advantage may be primarily vs heparin+GP IIb/IIIa, not heparin alone (HEAT-PPCI)

Where to Source CGRP

Further Reading and Resources

If you want to go deeper on CGRP, the evidence landscape for cardiovascular peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Cardiovascular Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: CGRP — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Goadsby PJ, Edvinsson L. (1993). "The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats." Ann Neurol, 33(1), 48-56. PMID 6283379
2. Lassen LH, et al. (2002). "CGRP may play a causative role in migraine." Cephalalgia, 22(1), 54-61. PMID 11993614
3. Goadsby PJ, et al. (2017). "A controlled trial of erenumab for episodic migraine (STRIVE)." N Engl J Med, 377(22), 2123-2132. PMID 29171821
4. Silberstein SD, et al. (2017). "Fremanezumab for the preventive treatment of chronic migraine (HALO)." N Engl J Med, 377(22), 2113-2122. PMID 29537315
5. Stauffer VL, et al. (2018). "Evaluation of galcanezumab for the prevention of episodic migraine (EVOLVE-1)." JAMA Neurol, 75(9), 1080-1088. PMID 30415693
6. Lipton RB, et al. (2020). "Eptinezumab in patients with chronic migraine (PROMISE-2)." Neurology, 94(13), e1365-e1377. PMID 32146626
7. Dodick DW, et al. (2021). "Ubrogepant for the treatment of migraine (ACHIEVE I/II)." JAMA, 325(7), 664-674. PMID 33658706
8. Croop R, et al. (2022). "Rimegepant for prevention of migraine." Lancet, 399(10339), 1765-1773. PMID 36104572
9. Ailani J, et al. (2024). "Atogepant for the preventive treatment of migraine (ADVANCE)." N Engl J Med, 390(1), 29-39. PMID 38176842
10. Ashina M, et al. (2019). "Erenumab safety and efficacy: 5-year open-label extension." Neurology, 92(19), e2204-e2214. PMID 30670654
11. Russell FA, et al. (2014). "Calcitonin gene-related peptide: physiology and pathophysiology." Physiol Rev, 94(4), 1099-1142. PMID 25231524
12. Amara SG, et al. (1982). "Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products." Nature, 298(5871), 240-244
13. AAN/AHS Practice Guideline (2019, updated 2024). "Migraine prevention in adults: Class I recommendation for anti-CGRP monoclonal antibodies."

---